Provided by Tiger Trade Technology Pte. Ltd.

Chemomab Therapeutics Ltd.

1.19
-0.4200-26.09%
Post-market: 1.200.0099+0.83%17:59 EDT
Volume:677.08K
Turnover:886.27K
Market Cap:8.72M
PE:-1.18
High:1.67
Open:1.62
Low:1.05
Close:1.61
52wk High:3.58
52wk Low:1.05
Shares:7.33M
Float Shares:6.14M
Volume Ratio:3.13
T/O Rate:11.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0070
EPS(LYR):-1.4103
ROE:-82.17%
ROA:-46.27%
PB:1.00
PE(LYR):-0.84

Loading ...

Chemomab Therapeutics Ltd - Unit Signs Amendment No. 1 to Merger Agreement with Scipher Medicine - SEC Filing

THOMSON REUTERS
·
1 hour ago

Chemomab Therapeutics: Unit to Redomicile into U.S., Merge with Scipher Medicine - SEC Filing

THOMSON REUTERS
·
1 hour ago

Chemomab Amends Domestication Merger Terms Ahead of Planned Scipher Deal

Reuters
·
1 hour ago

ADRs Close Lower; Chemomab Therapeutics Ltd. Declines 24%

Dow Jones
·
Sep 29

Chemomab Director Neil Harris Cohen Disposes of $6,515.40 in ADS Shares

Reuters
·
Sep 01

Chemomab CEO Adi Mor Presents at H.C. Wainwright Global Investor Conference

Reuters
·
Aug 31

Chemomab Therapeutics Q2 Operating Expenses USD 2.241 Million

THOMSON REUTERS
·
Aug 19

Chemomab Q2 FY26 Net Loss Widens to $2.2 Million

Reuters
·
Aug 19

Chemomab Therapeutics Ltd - Nebokitug Ra Phase 2 Clinical Trial Expected to Begin in H1 2027 and Read Out in H1 2028

THOMSON REUTERS
·
Aug 19

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 19

Chemomab Therapeutics Ltd - Cash, Cash Equivalents and Short-Term Bank Deposits were $6.7 Million as of June 30, 2026

THOMSON REUTERS
·
Aug 19

Chemomab Therapeutics Ltd Expected to Post a Loss of 15 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)

TIPRANKS
·
Jul 15

Adrs End Lower; Chemomab Therapeutics Ltd. Declines 29%

Dow Jones
·
Jul 09

Top Midday Decliners

MT Newswires Live
·
Jul 09

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an Ai-powered Phase 2 Trial in Rheumatoid Arthritis

THOMSON REUTERS
·
Jul 08

Chemomab: Combined Co Valued at $150 Mln Before Concurrent $30 Million Private Placement from Top- Tier Investors

THOMSON REUTERS
·
Jul 08

Chemomab Therapeutics: Combined Company to Operate as Scipher Medicine Corporation & Trade on NASDAQ Under Ticker Symbol “scip”

THOMSON REUTERS
·
Jul 08

Chemomab Therapeutics: Chemomab Shareholders to Own About 32% & Scipher Equity Holders Expected to Own About 68% of Combined Co Post-merger

THOMSON REUTERS
·
Jul 08

Chemomab: Co, Precision Medicine Pioneer Scipher Medicine Merger Deal to Advance Nebokitug in an Ai-powered Phase 2 Trial in Rheumatoid Arthritis

THOMSON REUTERS
·
Jul 08